Response to McKinnell et al's original article "cost-benefit analysis from the hospital perspective of universal active screening followed by contact precautions for methicillin-resistant Staphylococcus aureus carriers"

In a 2011 US study, targeted screening was associated with lower costs and better outcomes than a policy of no screening, whereas universal screening was associated with an average cost-effectiveness ratio of €11,769 per MRSA infection.6 In a second cost-effectiveness analysis, targeted screening st...

Ausführliche Beschreibung